BioWorld

June 23, 2008

Rare Pulmonary Fibrosis may Have Blockbuster Potential

A handful of companies are working to develop a treatment for a rare lung disorder called pulmonary fibrosis that, by some estimates, could present a $500 million to $1.5 billion market opportunity. (BioWorld Financial Watch) Read More

Money Raised By Month

Stock Winners and Losers For The Week

Biotechnology Company Deals With Other Biotechnology Companies: May 16 - June 19, 2008

Biotechnology Company Deals With Miscellaneous Companies: May 16 - June 19, 2008

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: May 16 - June 19, 2008

Biotech -- Biotech Collaborations: Modified Agreements: May 16 - June 19, 2008

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...